On October 28, 2021 AbClon (CEO Jong-seo Lee) and Lee Ensage (CEO Lee Bong-hee) reported business partnership agreement for joint development of CAR-NK cell therapy using gene editing technology (MOU) (Press release, AbClon, OCT 28, 2021, View Source;wr_id=150 [SID1234638632]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AppClone developed CAR-T through joint research with Ensage. Beyond platform technology CAR-NK expanding the scope of research and development with technology, In particular, the strategy is to target the cell therapy market from various angles by combining the company’s antibody discovery technology with Nsage’s gene scissors technology.

CAR-NK Cell therapy is a recombinant antigen receptor(CAR, Chimeric Antigen Receptor) Natural killer cells(NK cell) It is a cell therapy product that combines, NK cells and destroys abnormal cells or cancer. Responsible for immunity.

CAR-NK NK cells used to manufacture cell therapy products are isolated from the blood of healthy people. After culturing, these cells are GVHD (graft-versus-host disease), which is a rejection reaction to injection of other cells,Side effects The advantage is that it is low and mass production is possible. CAR-NK cell therapy has not yet been approved at home or abroad, but , is a pipe that global Big Pharma is trying to dominate. As a line, a lot of research and development is underway worldwide.

NSAGE uses a large amount of gene editing Cas12a material and Automated factory-type cell therapy production platform ‘Harmony’ Holds. NSAGE’s gene editing platform is a technology that targets specific targets for incurable diseases, existing stem cells. It is evaluated that it can overcome the limitations of treatment. Major The pipeline is a hemophilia target CAR-NK cell therapy.

AbClone is a new epitope(Epitope, antigenic determinant) Antibody discovery technology targeting ‘NEST (Novel Epitope Screening) Technology)’ has a platform. The NESTplatform provides a large-scale antibody database. It is a technology that can be used in the development of various cell gene therapy products,the company utilizes this to develop antibodies suitable for the purpose. We plan to select CAR-NK and apply it to the development of cell therapy. past 6month IND Blood cancer applied CAR-T Cell therapy ‘AT101’also NEST platform It was discovered through.

Jong-seo Lee, CEO of AppClon, said "the cooperation between the two companies and Through technological convergence, CAR-NK expands the pipeline to cell therapy CAR We will lay the foundation to lead the related industry by upgrading our technology"he emphasized.

Nsage CEO Lee Bong-hee said "AppClone’s Antibody discovery technology and CAR-T technology and our Cas12a gene scissors technology and NK automated production using domain libraries for cell activation, etc., Based on close cooperation between the two companies, highly effective and low-cost allogeneic CAR-NK cells for target cancers such as lung cancer remedy He said that he expects to be able to secure the pipeline early".